Medicare Enrolled
Dr. Sramila Aithal, MD
Medical Oncology · Bensalem, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Aithal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Aithal?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Aithal
Dr. Sramila Aithal is a medical oncology specialist in Bensalem, PA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Aithal performed 23,257 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Aithal received a total of $580,781 from 64 pharmaceutical and/or device companies across 604 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Aithal is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 8% volume in PA
$580,781 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗23,257
Medicare services
Top 8% in PA for medical oncology
Not available
Unique patients (not deduplicated)
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
11,850 | $0 | $6 |
| Denosumab injection (Prolia/Xgeva) | 5,100 | $18 | $68 |
| Iron infusion (Monoferric) | 1,500 | $16 | $73 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,490 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 930 | $1 | $122 |
| Injection, granisetron hydrochloride, 100 mcg | 580 | $0 | $25 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
426 | $97 | $224 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
321 | $13 | $105 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
180 | $112 | $686 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
164 | $25 | $152 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
135 | $11 | $73 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
125 | $70 | $148 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
117 | $12 | $93 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
85 | $2 | $19 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
68 | $53 | $304 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
51 | $1 | $9 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
50 | $28 | $249 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
20 | $63 | $157 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
19 | $129 | $343 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
17 | $151 | $301 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
16 | $109 | $297 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
13 | $146 | $412 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
8.8% high complexity
87.7% medium
3.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$580,781
Total received (2018-2024)
Avg $82,969/year across 7 years
Top 0% in PA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
64
Companies
604
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$141,011
2023
$150,570
2022
$86,489
2021
$77,454
2020
$55,503
2019
$51,528
2018
$18,224
Payments by company (2024)
PFIZER INC.
$53,535
Gilead Sciences, Inc.
$45,740
Daiichi Sankyo Inc.
$15,026
Lilly USA, LLC
$10,938
AstraZeneca Pharmaceuticals LP
$7,509
Merck Sharp & Dohme LLC
$5,729
Novartis Pharmaceuticals Corporation
$1,677
Ipsen Biopharmaceuticals, Inc
$223
ABBVIE INC.
$78
EAGLE PHARMACEUTICALS, INC.
$61
Alnylam Pharmaceuticals Inc.
$50
PUMA BIOTECHNOLOGY, INC.
$40
Stemline Therapeutics Inc.
$37
Coherus Biosciences Inc.
$31
SOBI, INC
$27
GENZYME CORPORATION
$27
Janssen Biotech, Inc.
$25
E.R. Squibb & Sons, L.L.C.
$25
Bayer Healthcare Pharmaceuticals Inc.
$25
Genmab U.S., Inc.
$24
Incyte Corporation
$24
Regeneron Healthcare Solutions, Inc.
$23
Mirati Therapeutics, Inc.
$23
Adaptive Biotechnologies Corporation
$22
Myriad Genetic Laboratories, Inc.
$21
GlaxoSmithKline, LLC.
$21
ADC Therapeutics America, Inc.
$17
Acrotech Biopharma Inc.
$16
Aveo Pharmaceuticals, Inc.
$16
Top 3 companies account for 81.1% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$172,878
Gilead Sciences, Inc.
$109,425
Seagen Inc.
$72,787
Lilly USA, LLC
$61,831
Daiichi Sankyo Inc.
$49,249
Novartis Pharmaceuticals Corporation
$40,099
AstraZeneca Pharmaceuticals LP
$24,139
Merck Sharp & Dohme LLC
$12,296
Puma Biotechnology, Inc.
$12,048
Eli Lilly and Company
$5,625
NOVARTIS PHARMACEUTICALS CORPORATION
$4,388
PUMA BIOTECHNOLOGY, INC.
$3,034
GENZYME CORPORATION
$2,895
Fresenius Kabi USA, LLC
$2,570
PFIZER INTERNATIONAL LLC
$1,800
Eisai Inc.
$1,542
Merck Sharp & Dohme Corporation
$1,301
E.R. Squibb & Sons, L.L.C.
$438
Ipsen Biopharmaceuticals, Inc
$223
EAGLE PHARMACEUTICALS, INC.
$204
Amgen Inc.
$189
Janssen Biotech, Inc.
$180
ABBVIE INC.
$93
Takeda Pharmaceuticals U.S.A., Inc.
$92
Coherus Biosciences Inc.
$87
Astellas Pharma US Inc
$84
G1 Therapeutics, Inc.
$80
Genentech USA, Inc.
$74
AbbVie Inc.
$64
ADC Therapeutics America, Inc.
$54
Celgene Corporation
$53
Stemline Therapeutics Inc.
$52
Bayer Healthcare Pharmaceuticals Inc.
$51
Alnylam Pharmaceuticals Inc.
$50
Bayer HealthCare Pharmaceuticals Inc.
$47
Aadi Bioscience, Inc.
$44
Genmab U.S., Inc.
$44
BeiGene USA, Inc.
$43
Exelixis Inc.
$42
Kyowa Kirin, Inc.
$42
Foundation Medicine, Inc.
$41
Acrotech Biopharma LLC
$40
R-Pharm US LLC
$38
Acrotech Biopharma Inc.
$33
SOBI, INC
$27
Kite Pharma, Inc.
$24
Incyte Corporation
$24
Alexion Pharmaceuticals, Inc.
$23
Regeneron Healthcare Solutions, Inc.
$23
Mirati Therapeutics, Inc.
$23
MorphoSys, US Inc.
$22
Adaptive Biotechnologies Corporation
$22
Myriad Genetic Laboratories, Inc.
$21
GlaxoSmithKline, LLC.
$21
Pharmacosmos Therapeutics Inc.
$19
Organon LLC
$18
Heron Therapeutics, Inc.
$18
Pharmacyclics LLC, an AbbVie Company
$18
Blueprint Medicines Corporation
$17
Aveo Pharmaceuticals, Inc.
$16
SERVIER PHARMACEUTICALS LLC
$15
Taiho Oncology, Inc.
$14
Emmaus Medical, Inc.
$13
Boehringer Ingelheim Pharmaceuticals, Inc.
$12
Top 3 companies account for 61.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALUNBRIG · AMVUTTRA · AYVAKIT · Aliqopa · BELEODAQ · BRUKINSA · Blincyto · CALQUENCE · CINVANTI · COSELA · CYRAMZA · Cabometyx · DOPTELET · ELIQUIS · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · EXKIVITY · Endari · Enhertu · FOLOTYN · FOTIVDA · FOUNDATIONONE · FYARRO · Fyarro · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Ixempra · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MYRISK · NERLYNX · Nerlynx · Nplate · Nubeqa · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · Onivyde · Orserdu · PEMAZYRE · PEMFEXY · PIQRAY · PLUVICTO · POTELIGEO · Pomalyst · REBLOZYL · Rozlytrek · SARCLISA · SCEMBLIX · SUTENT · Stimufend · Stivarga · TALZENNA · TASIGNA · TECENTRIQ · TUKYSA · Tazverik · Tibsovo · Tivdak · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VPRIV · Vanflyta · XALKORI · Xospata · Zydelig · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Medical oncologists in nearby ZIP areas
114
County median income
$111,951
Nearest hospital to ZIP centroid (approximate)
ROTHMAN ORTHOPAEDIC SPECIALTY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Aithal is a mixed practice specialist, with above-average Medicare volume (top 8% in PA), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Aithal experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Aithal performed 11,850 anti-nausea injection (fosaprepitant) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Aithal receive payments from pharmaceutical companies?
Yes. Dr. Aithal received a total of $580,781 from 64 companies across 604 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Aithal's costs compare to other medical oncologists in Bensalem?
Dr. Aithal's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Aithal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Bensalem
Browse medical oncologists in Bensalem ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in PA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in PA
Which PA medical oncologists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
Seagen Inc. Payments to Doctors
See all physicians who received payments from Seagen Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology